Recent 8-K filings for LRMR
Highest-materiality recent filing
Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M
- Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
- Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.
-
Larimar shareholders approve increase in authorized shares to 215M; reelect three directors
Shareholders approved amendment increasing authorized common shares from 115M to 215M (89.7M for, 1.05M against).
-
Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M
Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
-
Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission
Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
-
Larimar Therapeutics posts updated corporate presentation; no material news disclosed
Company made updated corporate slide presentation available on its website on March 9, 2026.
-
Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.
-
FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.
-
Larimar Therapeutics exchanges 2.5M common shares for Series A convertible preferred with Blue Owl
Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares (10:1 conversion ratio).
-
Larimar Therapeutics reports preliminary cash position of $136.9M as of Dec 31, 2025
Preliminary cash, cash equivalents and marketable securities of $136.9M as of Dec 31, 2025, unaudited.
-
Larimar exchanges 2.5M common shares for 250K convertible preferred with Blue Owl
Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares.
-
Larimar posts corporate deck; no material new facts in filed excerpt
Larimar posted an updated corporate presentation on its website on November 10, 2025.
-
Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study
Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.
-
Larimar posts updated corporate presentation; no financial or clinical data in filing
The 8-K filed on Oct 14, 2025, indicates an updated slide deck was posted on the company website.
-
Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN
10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).
-
Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026
Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.
-
Larimar Therapeutics prices $64.4M common stock offering at $3.20 per share
Offering of 18,750,000 shares of common stock at $3.20; underwriters' over-allotment of 2,812,500 shares exercised in full.
-
Larimar Therapeutics reports preliminary cash balance of $138.5M as of June 30, 2025
Preliminary unaudited cash, cash equivalents and marketable securities of $138.5M as of June 30, 2025.
-
Larimar gets FDA safety database guidance; nomlabofusp BLA submission planned for Q2 2026
FDA recommends safety database of ≥30 participants with 6-month continuous exposure (≥10 with 1-year), majority on 50 mg dose.
-
Larimar posts updated corporate presentation for investor meetings
Company posted updated slide presentation on June 23, 2025 for use in meetings with investors and analysts.
-
Larimar Therapeutics holds 2025 Annual Meeting; all proposals pass
Thomas E. Hamilton elected Class II director with 46.5M votes for, 4.3M withheld.
-
Larimar posts updated corporate presentation; no material new data
Updated slide deck dated May 5, 2025 posted on company website.
-
Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint
Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.
-
Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025
FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.
-
Larimar grants performance-based PSUs to four top executives
CEO Carole Ben-Maimon receives 100,000 PSUs tied to regulatory milestones.
-
Larimar Therapeutics posts updated corporate presentation on website
Company filed an 8-K announcing an updated slide presentation posted on January 10, 2025.
-
Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.
-
Filed 8-K on Nov 18, 2024, attaching a corporate presentation (Exhibit 99.1).
-
Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025
Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.
-
Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program
Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.
-
Larimar posts updated corporate presentation; no specific changes disclosed
Company posted updated slide presentation on its website on June 10, 2024.
-
Jonathan Leff and Jeffrey Sherman re-elected as Class I directors with ~40.7M and ~51.1M votes for, respectively.
-
FDA selects Larimar's nomlabofusp for START pilot program to accelerate FA development
FDA selects nomlabofusp for START pilot program based on potential clinical benefit and program readiness.
-
FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia
FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.
-
Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025
Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.55 · Most common event other_material